IN THE CLAIMS:

All claim amendments and cancellations are made without prejudice or disclaimer. Please amend the claims as follows:

Listing of the claims:

1. (Canceled)

2. (Currently Amended) A process for detecting and quantifying a nucleic acid of interest in at least one sample, the process comprising:

administering at least 100µl of the at least one sample to a solid carrier capable of absorbing the at least one sample;

drying the solid carrier;

extracting a representative part of the at least one sample from the solid carrier with a nucleic acid isolation solution;

detecting the nucleic acid of interest, if present, in the representative part of the at least one sample; and

quantifying the nucleic acid of interest in the at least one sample.

3. (Currently amended) The process according to claim ~~1~~2, wherein at least ~~100~~ 200 µl of the at least one sample is administered to the solid carrier.

4. (Previously presented) The process according to claim 3, wherein at least 250 µl of the at least one sample is administered to the solid carrier.

5. (Currently amended) The process according to claim 2~~1~~, further comprising identifying the nucleic acid of interest.

6. (Currently amended) The process according to claim 2~~1~~, wherein at least two samples are administered to the solid carrier.

7. (Currently amended) The process according to claim 2~~1~~, further comprising administering a known amount of a reference nucleic acid to the solid carrier.

8. (Currently amended) The process according to claim 2~~1~~, wherein the representative part of the solid carrier comprises the whole of the at least one sample.

9. (Currently amended) The process according to claim 2~~1~~, wherein the representative part of the solid carrier comprises the whole of the solid carrier.

10. (Previously presented) The process according to claim 6, wherein the representative part of the solid carrier comprises one of the at least one samples.

11. (Currently amended) The process according to claim 2~~1~~, wherein the nucleic acid isolation solution comprises a chaotropic nucleic acid isolation lysis buffer.

12. (Currently amended) The process according to claim 2~~1~~, wherein the nucleic acid of interest comprises RNA.

13. (Previously presented) The process according to claim 12, wherein the RNA is selected from the group consisting of mitochondrial RNA, viral RNA, messenger RNA, and combinations of any thereof.

14. (Currently amended) The process according to claim 2~~1~~, wherein the nucleic acid of interest is of a viral origin.

15. (Previously presented) The process according to claim 14, wherein the viral nucleic acid comprises a retroviral nucleic acid.

16. (Previously presented) The process according to claim 13, wherein the viral RNA comprises at least one of HIV or HTLV.

17. (Previously presented) The process according to claim 13, wherein the viral RNA comprises HIV-1.

18. (Currently amended) The process according to claim 2~~1~~, wherein the solid carrier comprises filter-paper.

19. (Currently amended) The process according to claim 2~~1~~, further comprising genotyping a mutant from which the nucleic acid of interest originates.

20. (Currently amended) The process according to claim 2~~1~~, wherein the at least one sample comprises a ~~precious~~ bodily fluid.

21. (Currently amended) The process according to claim 2~~1~~, wherein the at least one sample is selected from the group consisting of blood, plasma, ~~mothers~~ mother's milk, sputum, liquor, saliva, urine, and combinations of any thereof.

22. (Currently amended) The process according to claim 2~~1~~, wherein the at least one sample comprises a droplet of whole blood.

23. (Currently amended) The process according to claim 2~~1~~, wherein the at least one sample is a plasma sample.

24. (Currently amended) The process according to claim 2~~1~~, wherein detecting or quantifying the nucleic acid comprises amplifying the nucleic acid.

25. (Previously presented) The process according to claim 24, wherein amplifying the nucleic acid comprises real-time monitored amplification.

26. (Currently amended) The process according to claim 2~~1~~, wherein detecting or

quantifying the nucleic acid is performed with an end-point read-out system.

27. (Currently amended) The process according to claim 2~~1~~, further comprising determining a ratio between different nucleic acids, if present, in the at least one sample.

28-35 (Canceled)